Details for Patent: 7,781,448

Summary for Patent: 7,781,448

Title:	Once daily dosage forms of trospium
Abstract:	A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
Inventor(s):	Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
Assignee:	TCD ROYALTY SUB LLC
Application Number:	US11/889,962
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Scope and claims breakdown for US Patent 7,781,448 (trospium once-a-day XR/DR oral compositions)

US Patent 7,781,448 claims a once-daily oral trospium chloride formulation built from two different trospium-containing pellet components: one XR (extended release) and one DR (delayed release), with optional IR (immediate release). The core claim scope is narrowed to (i) specific dose ranges (25 to 80 mg trospium chloride), (ii) pharmacokinetic exposure targets (steady-state trough-to-peak blood levels about 0.5 to 6.0 ng/mL), and (iii) GI site delivery (at least a portion released in the lower GI tract, including specific embodiments for colon or pH about 7 triggering enteric behavior). Dependent claims further lock in polymer lists, pellet architecture, and multi-unit dose ratios (including a specific 60 mg, 1:1 split embodiment).

On the strength side for enforcement, the claims are structurally and functionally specific: they tie together pellet-internal composition, outer coatings, release logic (enteric vs release controlling), and a quantitative PK window linked to once-daily administration comparable to twice-daily 20 mg IR trospium chloride exposure, plus a method-of-preparation route using granulation and coating steps.

---

What does US 7,781,448 claim for once-daily trospium XR/DR?

Independent claim 1 (composition of matter) requires:

1. Oral pharmaceutical composition for once-a-day trospium
2. Two different trospium-containing components:
   • First component: at least one of XR and/or DR
   • Second component: at least one of XR, DR, or IR
   • The first and second components are different from each other
3. Dose: 25 to 80 mg trospium chloride
4. PK window at once daily: steady state blood levels of trospium:
   • minimum ~0.5 ng/mL
   • maximum ~6.0 ng/mL
5. Polymer constraint: includes at least one polymer selected from enteric polymers and/or release controlling polymers
6. Release site: at least a portion releases trospium in the lower GI tract

This claim is not a generic “once-daily trospium formulation.” It is a specific delivery system tied to XR/DR/IR component differences, polymer class selection, dose range, and blood level targets.

Claim 1’s functional-to-structural hook

The most enforcement-relevant combination is:

• Lower GI release (enteric-like behavior) +
• Release profile control (XR logic) +
• Quantitative steady-state blood concentration window +
• Two different trospium-containing components (first and second differ)

That pairing creates an “engineering envelope” that is harder for competitors to design around than claims limited to generic excipient lists alone.

---

Is the patent limited to pellet-based XR/DR systems or does it cover other dosage forms?

Claim 1 itself is broad enough to cover an “oral pharmaceutical composition,” including multiple solid oral types listed in claim 19. However, dependent claims introduce strong sub-scopes.

Oral dosage forms explicitly covered

• Granule, tablet, pellet, beadlet, powder, sachet, capsule, gel, dispersion, solution, suspension (claim 19)
• Rapidly dispersible tablet (claim 20)
• Layered tablets/pellets/beadlets with at least two trospium-containing layers each including XR/DR/IR components (claim 21)

Pellet architecture is explicitly claimed

• Each one of XR component and DR component is in the form of pellets (claim 12)
• DR pellets with “consisting essentially of” components and pellet coating stack (claim 13)
• XR pellets with “consisting essentially of” components and coating stack (claim 13)

Because claim 13 uses “consisting essentially of”, it can be a more enforceable form boundary than open “comprising” language, limiting permissible excipient substitution.

---

What polymer compositions define the XR and DR portions in the claims?

XR component polymer list (claims 4 and 31)

XR includes at least one release controlling polymer selected from:

• Copolymers of acrylic and methacrylic acid esters
• Ethylcellulose aqueous dispersions
• Hydroxyethyl cellulose
• Hydroxypropyl cellulose
• Hydroxypropyl methylcellulose
• Hydroxypropyl methylcellulose
• Polyvinylpyrrolidone
• Polyvinylpyrrolidone/vinyl acetate copolymer
• Polyethylene glycols
• Combinations

This list is broad across common sustained-release hydrophilic and hydrophobic excipients, which makes “XR polymer identity” less likely to be a narrow escape route unless the competitor’s release mechanism is demonstrably outside the listed categories.

DR component enteric polymer list (claims 5 and 32)

DR includes at least one enteric polymer selected from:

• Cellulose acetate phthalate
• Hydroxypropyl methylcellulose phthalate
• Polyvinyl acetate phthalate
• Hydroxypropyl methylcellulose acetate succinate
• Cellulose acetate trimellitate
• Hydroxypropyl methylcellulose succinate
• Cellulose acetate succinate
• Cellulose acetate hexahydrophthalate
• Cellulose propionate phthalate
• Multiple acrylic/methacrylic/maleate-copolymer enteric systems
• Zein, shellac, copal collophorium
• Carboxymethyl ethylcellulose
• Methacrylic acid / methacrylic acid methyl ester copolymers
• Combinations

This is a typical enteric polymer universe. The patent’s enforceability hinges less on a single enteric polymer and more on the pellet stack + release-site claim language and the PK outcome.

---

What dose and PK limits matter most for infringement risk?

Dose range (claims 1 and 27)

• 25 to 80 mg trospium chloride in the claimed composition.

Quantitative steady-state blood levels (claims 1 and 27)

Once-daily administration must provide steady-state blood levels of trospium:

• ~0.5 ng/mL minimum
• ~6.0 ng/mL maximum

Comparative PK benchmark (claims 2 and 28)

The patent ties once-daily exposure to the clinical benchmark:

• Comparable steady state blood levels achieved with twice daily 20 mg IR trospium chloride tablets.

This is a strong litigation anchor because defendants often must argue non-infringement on either:

• the PK window, or
• different component structures/combination architecture that yields different absorption.

---

Are adverse-effect minimization and symptom outcomes part of the claim scope?

Yes, but only in dependent form.

• Claim 2 requires once-a-day administration:
  • minimizes adverse side effects and
  • provides steady state blood levels comparable to twice-daily 20 mg IR.

Adverse effects explicitly listed (claim 3):

• dry mouth, headache, constipation, dyspepsia, abdominal pain, or combinations.

This will usually function as a supporting claim limitation rather than the main non-infringement lever, unless a challenger can show the competitor formulation produces different incidence profiles.

---

What “lower GI tract release” embodiments are specified?

Claim 1 sets the baseline:

• “wherein at least a portion of which releases trospium in the lower GI tract.”

Dependent embodiments sharpen where:

• DR component releases at pH about 7 (claim 16)
• DR component releases in lower intestine (claim 17)
• DR component releases in colon (claim 18)

For enforcement planning, these dependent limitations map to enteric dissolution behavior and location-specific release and can tighten claim construction if the reference formulation’s enteric behavior is contested.

---

What are the key component-count and component-difference requirements?

“First” vs “Second” trospium component must differ (claim 1)

• First component uses XR and/or DR.
• Second component can use XR/DR/IR.
• The two trospium-containing components are different from each other.

This matters for infringement design-around strategies:

• A competitor cannot simply use two identical sustained-release units. The claims target different XR/DR compositions across at least two trospium populations.

Optional IR included as a third component in multiple claims

• IR portion capped in claims 6, 34 (and dependent method claims):
  • IR contains not more than about 20 mg trospium chloride
• Claims 7-10 define combinations of IR with XR and/or DR:
  • IR + DR
  • IR + XR
  • IR + XR + DR
  • XR + DR

---

What exact pellet compositions are recited in the detailed “consisting essentially of” claims?

DR pellets (claim 13)

DR pellets consist essentially of: a) trospium chloride
b) sugar core
c) hydroxypropyl methylcellulose
d) enteric polymer coating delaying release after administration
e) triethyl citrate
f) protective overcoating
g) talc

XR pellets (claim 13)

XR pellets consist essentially of: a) trospium chloride
b) sugar core
c) hydroxypropyl methylcellulose
d) surface coating controlling release profile
e) protective overcoating
f) talc

This is a high-information limit. “Consisting essentially of” can still allow unspecified minor excipients, but it constrains deliberate substitution of core functional materials (e.g., switching from HPMC-based core to a different matrix polymer) if the competitor’s pill composition drifts out of the defined structural essentials.

Specific dose split (claim 14, also supported in claim 26)

• Claim 14: XR about 30 mg, DR about 30 mg
• Claim 25-26: 60 mg total with equally divided between enteric coated pellets and extended release pellets

“Mixture ratio” embodiment (claim 24)

• Ratio of enteric coated pellets : extended release pellets = 1:1
• Enteric coated pellets “consist essentially of”:
  • trospium chloride, sugar spheres, HPMC, methacrylic acid copolymer, triethyl citrate, talc
• XR pellets “consist essentially of”:
  • trospium chloride, sugar spheres, HPMC, ethyl cellulose, talc

This claim is particularly actionable because it defines a concrete excipient stack for a specific 1:1 mixture dose system.

---

What layered or multi-unit architectures are claimed?

• Claim 15: each component can be in the form of a layer
• Claim 21: layered tablet/pellet/beadlet comprising at least two trospium-containing layers, each layer includes at least one of XR/DR/IR components

These expansions can capture non-pellet packaging architectures, but they still keep the substance of claim 1’s XR/DR/IR component logic.

---

What method-of-preparation claims increase process-enforcement leverage?

US 7,781,448 includes method claims that can broaden enforcement via process infringement (or via inducement/contributory theories), depending on how generic manufacturers and authorized generics make the products.

Core method (claim 27)

Method to prepare once-a-day trospium composition:

1. Prepare first trospium component with XR and/or DR; include enteric and/or release-controlling polymers
2. Prepare second trospium component with XR/DR (differing from first)
3. At least one XR or DR component delivers to lower GI tract
4. Optional IR component
5. Combine into composition:
   • 25 to 80 mg trospium chloride
   • PK steady-state blood window 0.5 to 6.0 ng/mL

Granulation + coating method (claims 33-37)

• XR/DR components prepared by granulating trospium chloride with pharmaceutically acceptable carrier to produce pellets, then coating with:
  • release-controlling polymer (for XR) or
  • enteric polymer (for DR)
• IR component granulated to produce IR pellets
• Combining XR/DR/IR into one composition

Layered coating method using trospium-coated cores (claims 38-44)

• Apply layer of trospium chloride to core (carrier often sugar sphere)
• Coat trospium-coated core with release controlling or enteric polymer
• Then combine XR and DR components, optionally add IR
• IR limited to not more than about 20 mg (claims 41-44)

If a competitor uses different manufacturing architecture that avoids granulation and/or the specified layered coating scheme, they may argue process non-infringement. But the presence of multiple method claim styles reduces easy avoidance.

---

How does the patent map to a typical once-daily trospium clinical product profile?

The claims target a “once daily replacement” for twice-daily 20 mg IR. Translating that into scope:

• Once-daily system must produce a sustained exposure plateau (min 0.5 ng/mL, max 6.0 ng/mL) and not fall outside the window.
• Enteric behavior delays absorption, producing a controlled lower GI release profile that helps extend exposure and/or reduce peak-related adverse events.

The patent also explicitly claims bladder dysfunction indications:

• urinary frequency, urgency, nocturia, urge-incontinence due to detrusor instability, urge syndrome, detrusor hyperreflexia (claim 22)

This supports method-of-use or formulation-for-indication framing even though the main independent claim is composition-based.

---

What exact competitive design-arounds are most plausible against this claim set?

Within the specific claim language you provided, the most plausible non-infringement vectors are:

1. Avoid satisfying the PK window (0.5 to 6.0 ng/mL at steady state once daily).
2. Use components that are not “different” from each other under the claim’s XR/DR/IR component-difference requirement.
3. Eliminate lower GI release behavior, or ensure that the competing product’s release is primarily upper GI/systemic early rather than “lower GI” as claimed.
4. Break the “consisting essentially of” pellet compositions for the narrow dependent embodiments (claim 13) by changing core polymer/citricizer/enteric system architecture beyond what is permissible in “consisting essentially of.”
5. Avoid manufacturing steps captured in the method claims if seeking process non-infringement (granulation + coating or trospium-on-core layering sequences).

The strongest positions for a patentee usually come from: (i) PK-based infringement proof using comparative blood level data and (ii) pellet excipient stack matching, especially for claim 13 and claim 24-type embodiments.

---

What is the size of the “claim coverage” in practical terms?

Broad coverage layer (claim 1 + claim 19):

• Covers multiple oral dosage forms
• Covers a range of trospium doses (25 to 80 mg)
• Allows broad “polymer selected from” enteric and release controlling categories

Narrow coverage layer (claims 12-14, 13, 24-26):

• Pellet-specific and excipient-stack-specific (“consisting essentially of”)
• Sugar core + HPMC + triethyl citrate + talc + protective coatings for DR
• Sugar core + HPMC + protective coatings + talc + XR surface coating logic
• Specific 1:1 mixture and specific XR/enteric polymer exemplars in claim 24

Process coverage layer (claims 27, 33, 38):

• Manufacturing steps tied to granulation and coating or layered coating on cores

---

Key Takeaways

• Independent claim 1 is anchored to a once-daily trospium chloride oral composition using two different trospium-containing components (XR/DR and XR/DR/IR mix), delivering at least partial lower GI release and meeting a steady-state PK blood window of ~0.5 to 6.0 ng/mL.
• The claim set blends structure (XR/DR/IR components, pellets, polymer classes) with function (lower GI release and quantitative blood levels), strengthening enforcement leverage.
• Dependent claims (notably claim 13 and claim 24) narrow scope to specific pellet stacks defined by “consisting essentially of” language, including sugar core, HPMC, triethyl citrate, talc, protective overcoat, and enteric vs release controlling coating materials.
• Method claims capture granulation + coating and trospium-on-core layering routes, adding potential process-based infringement pathways.

---

FAQs

1. Does US 7,781,448 cover once-daily trospium tablets or only pellets?
It covers multiple oral dosage forms in claim 19 (including tablets and pellets), but pellet-specific excipient-stack limitations appear in dependent claims 12-14 and 13.

2. What dose range is protected under the independent claim?
Claim 1 requires 25 to 80 mg trospium chloride.

3. Is the PK blood level range required for infringement?
Under claim 1 and method claim 27, yes: once-daily administration must achieve steady-state blood levels approximately 0.5 to 6.0 ng/mL.

4. How is “lower GI tract” implemented in the claims?
Through enteric DR behavior: dependent claims specify pH ~7, lower intestine, and colon release, plus enteric polymer lists.

5. How do the dependent “consisting essentially of” pellet claims narrow protection?
They require particular excipient categories and stacks (e.g., DR pellets: sugar core, HPMC, enteric polymer coating, triethyl citrate, protective overcoat, talc; XR pellets: sugar core, HPMC, surface coating controlling release, protective overcoat, talc).

Drugs Protected by US Patent 7,781,448

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,781,448

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	493981
Australia	2004289223
Canada	2537103